Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ridogrel enemas in distal ulcerative colitis.

J J Auwerda1, F J Zijlstra, C J Tak

  • 1Department of Internal Medicine and Pathology, Ikazia Hospital, Montessoriweg 1, 3083 AN Rotterdam, The Netherlands. auwerda@mdl.azr.nl

European Journal of Gastroenterology & Hepatology
|May 8, 2001
PubMed
Summary

Ridogrel enemas significantly reduced mucosal thromboxane B2 (TxB2) levels in patients with ulcerative colitis. While some patients showed disease improvement, other inflammatory markers remained unchanged, suggesting a targeted effect of Ridogrel.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of prostanoids in ozone-induced changes in airway responsiveness: receptor activation-specific prostanoid release.

Environmental toxicology and pharmacology·2011
Same author

Diagnostic criteria in patients with complex regional pain syndrome assessed in an out-patient clinic.

Acta anaesthesiologica Scandinavica·2010
Same author

Increased plasma glutamate, glycine, and arginine levels in complex regional pain syndrome type 1.

Acta anaesthesiologica Scandinavica·2008
Same author

Peritoneal protein losses and cytokine generation in automated peritoneal dialysis with combined amino acids and glucose solutions.

Mediators of inflammation·2008
Same author

Interleukin-2-Deficient mice: effect on cytokines and inflammatory cells in chronic colonic disease.

Digestive diseases and sciences·2002
Same author

Neuroimmune alterations in the complex regional pain syndrome.

European journal of pharmacology·2001

Area of Science:

  • Gastroenterology
  • Inflammation Research
  • Pharmacology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Current treatments for UC have limitations and side effects.
  • Targeting specific inflammatory mediators may offer new therapeutic avenues.

Purpose of the Study:

  • To assess the efficacy of Ridogrel enemas in treating active left-sided ulcerative colitis.
  • To evaluate the impact of Ridogrel on disease activity and mucosal inflammatory mediators.

Main Methods:

  • An open-label, non-placebo-controlled pilot study involving eleven UC patients.
  • Patients received Ridogrel enemas (300 mg/40 ml daily) for four weeks.
  • Disease activity scores and mucosal concentrations of TxB2, PGE2, IL-6, and TNF-alpha were measured before and after treatment.

Related Experiment Videos

Main Results:

  • Ten out of eleven patients tolerated Ridogrel enemas well.
  • A significant decrease in mucosal thromboxane B2 (TxB2) concentration was observed in all patients.
  • Prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) levels remained unaltered.
  • Five patients experienced a decrease in disease score, but clinical improvement did not consistently correlate with endoscopic or histological changes.

Conclusions:

  • Ridogrel enemas demonstrated a selective reduction in mucosal TxB2 concentration in UC patients.
  • This finding suggests a potential targeted anti-inflammatory mechanism for Ridogrel in ulcerative colitis.